WO2003088949A2 - Matrix mit einer bioaktiven phospholipid-haltigen komponente - Google Patents
Matrix mit einer bioaktiven phospholipid-haltigen komponente Download PDFInfo
- Publication number
- WO2003088949A2 WO2003088949A2 PCT/EP2003/004030 EP0304030W WO03088949A2 WO 2003088949 A2 WO2003088949 A2 WO 2003088949A2 EP 0304030 W EP0304030 W EP 0304030W WO 03088949 A2 WO03088949 A2 WO 03088949A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- weight
- matrix
- matrix according
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a matrix with a bioactive, phospholipid-containing component and the use thereof.
- the substance class of the phospholipids are so-called complex lipids with amphiphilic, ie at the same time lipophilic and hydrophilic properties, which among other things enables them to form lipid bilayers in aqueous media.
- phospholipids are phosphodiesters in which the phosphoric acid is esterified on the one hand with a sphingosine or glyceride residue and on the other hand with choline, ethanolamine, serine, inositol or glycerol.
- Phosphatidylcholine is also known as lecithin and is also the eponym for a large group of special phospholipids, the lecithins.
- Phosphatidylserine and phosphatidylethanolamine are also known as cephalins.
- the lyso derivatives which also belong to this group, are formed by hydrolytic cleavage using specific phospholipases.
- Capsules containing phospholipids are well known from the prior art and mostly contain phospholipids as the coating substance. If phospholipids are used in the filling, i.e. in the capsule core, they mostly act in small proportions there as formulation aids with mostly solubilizing properties.
- the phospholipids Due to their amphiphilic properties, the phospholipids also serve as coating substances for the known liposomes and transferosomes. In In this context, they are used primarily because of their bioadhesive properties in the area of mucosal applications, with them being introduced in particular into the nasal and oral cavities.
- phospholipids are also used as surface-active formulation aids (surfactants).
- lysophospholipids are described as solubilizers for hydrophobic bioactive substances.
- Lecithin as a bioactive ingredient contains soft gelatin capsules, which are commercially available as KAL S lecithin and which contain 1,200 mg soy lecithin. However, in order to be able to accommodate this amount of lecithin in a capsule, capsule sizes must be selected that approach the centimeter limit and thus limited compliance.
- PS phosphatidylserine
- the PS obtained in this way or corresponding PS products is embedded in a hard fat in aqueous Systems can be stabilized.
- the suggestions made there are limited to soft gelatin capsules, which should have the special PS in the content.
- the system described there stabilizes the known hydrolysis-unstable phosphatidylserine, but it has the disadvantage that this formulation cannot be encapsulated.
- the encapsulation of phospholipids generally causes great problems, since, as described, they also act as emulsifiers and thus rapidly cause the as yet uncured (dried) casing to mix with the contents during the encapsulation process. As a result, the capsules leak in a relatively short time, they leak and are therefore no longer usable.
- the object of the present invention was therefore to provide a matrix with a bioactive, phospholipid-containing component which does not have the disadvantages of the prior art described and which are formulated in an economically justifiable manner can.
- the bioactive phospholipid components incorporated into the matrix should have sufficient stability for the most common uses, even in the encapsulated state.
- the bioactive component being 5 to 98% by weight of phosphatidylserine (PS) and 1 to 90% by weight of phosphatidylcholine (PC) and moreover 1 to 94% by weight of at least one further component the range of fat components of vegetable and / or animal origin, wax component, polyalcohol component and other physiologically compatible additives.
- PS phosphatidylserine
- PC phosphatidylcholine
- the phosphatidylserine or phosphatidylcholine portions contained therein are extremely stable with respect to the otherwise negative hydrolysis or the general breakdown of encapsulated lecithins. This is particularly pronounced with blends that are highly viscous and also have the property of thixotropy. Until now it was only known that highly viscous blends make lecithins more stable, however, these highly viscous mixtures could then no longer be encapsulated (see DE-OS 1 99 1 7 249). This is all the more surprising since phosphatidylserine in particular is known to be significantly less stable than other phospholipids.
- the compounds each preferably contain a residue which is derived from a C 2 -C 30 carboxylic acid bonded to the hydroxyl groups of the glycerol, in particular a C 12 -C 28 carboxylic acid.
- the acid residues can be linear or branched, saturated or mono- or polyunsaturated.
- residues which, by binding acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, arachic acid, behenic acid, lignoceric acid, R-linolenic acid, eicosapentaenoic acid, erucic acid, Nervonic acid, - or R-Eleostearic acid or parinic acid are formed.
- Residues which are formed by binding palmitic acid, stearic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, arachidonic acid or docosahexaenoic acid are particularly preferred.
- the acid residues bound to the two OH groups of the glycerol still available can be the same or different.
- Phosphatidylserine and phosphatidylcholine represent the bioactive part in the total matrix according to the invention; the other components give the overall matrix its advantageous properties due to their proportions.
- bioactive is understood to mean the action of phosphatidylserine and phosphatidylcholine in such a way that they develop a biological effect in the resorption area, on the transport route or at the destination in the living organism during or after their release from the total matrix , which usually applies to corresponding preparations in the human or veterinary field.
- This bioactive effect is of course not limited to the two phospholipids mentioned, but can also be developed by the other components involved in the overall matrix. However, their bioactive effect is not in the foreground for the matrix according to the invention.
- a matrix has been shown to be particularly suitable, the bioactive component of which contains 10 to 40% by weight and particularly preferably 15 to 30% by weight of phosphatidylserine. Also particularly suitable is a matrix whose bioactive component contains 2.0 to 20% by weight of phosphatidylcholine.
- compositionsen which consists of 10 to 70 wt .-% and particularly preferably 20 to 50 wt .-% of the fat component and / or 3 to 30 wt .-% and particularly preferably 5 to 20 wt .-% of the wax component, 1 to 30 wt .-% and particularly preferably 1 to 20 wt .-% of the polyalcohol component and / or 1, 0 to 5 wt .-% of other physiologically compatible additives.
- the matrix as a fat component can preferably be refined, hydrogenated and / or fractionated fats and in particular those which are rich in omega-3 and / or omega-6 fatty acids, such as docosahexaenoic acid, arachidonic acid, Eicosapentaenoic acid and conjugated linolenic acid, free fatty acids, especially omega-3 and omega-6 fatty acids, as a wax component preferably beeswax, candellila wax, shellack, paraffin, mono- or diglycerides, and also as a polyalcohol combination, preferably with a po contain ethyl en g ly kol, polysorbate, polyglycerol esters, sugar esters or sorbitan esters.
- omega-3 and / or omega-6 fatty acids such as docosahexaenoic acid, arachidonic acid, Eicosapentaenoic acid and conjugated linolenic acid, free fatty acids, especially omega-3 and omega-6
- the matrix can also advantageously tocopherols and their derivatives, tocotrienols and their derivatives, polycosanols and their derivatives, vitamins such as vitamins C and E, also in derivatized form, amino acids, in particular the essential, branched and non-proteinogenic such as theanine, amino acid derivatives such as Creatine, taurine, carnitine, phytosterols and their derivatives, (poly) -phenolic compounds and their derivatives such as catechol, phenolic acids such as gallic acid, hydroxycinnamic acids, coumarins, (iso-) flavonoids such as quercetin or genistein, lignans and lignins as well as tannin, saponins, mono -, Sesqui- and di-terpenes, carotenoids such as beta-carotene, lutein or lycopene, glucosinolates, fiber such as non-starch polysaccharides, extracts of plant and /
- the stabilization of phosphatidylserine and phosphatidylcholine according to the invention is effected in particular by further matrix components which are selected such that the total matrix (ie consisting of PS / PC and the other components) is solid at room temperature, to an extent that in the case of Use of fats (triglycerides) is the solid fraction of the triglyceride that can be determined by DSC> 80% at 23 ° C.
- the components are advantageously chosen so that the overall matrix exhibits the property of shear thinning, which can be achieved, for example, by the preferred use of a combination of fat and wax (eg beeswax) in connection with PC / PS in the matrix if the triglyceride contains one sufficiently high proportion of fixed, ie contains unmelted triglycerides.
- preferred matrix components have a saturated fatty acid content of over 50% and advantageously no more than four main triglyceride species are present.
- palm kernel oil in conjunction with beeswax has proven particularly advantageous here.
- the person skilled in the art can thus readily select matrices suitable according to the invention on the basis of criteria 1) the solid fraction of the triglyceride which can be determined by DSC is> 80% at 23 ° C., and 2) the fraction of saturated fatty acids is above 50%.
- the phosphatidylserine and phosphatidylcholine are stabilized by using a matrix which contains a polyalcohol component.
- this matrix can be somewhat more liquid, in particular glycerol being added as the polyalcohol component.
- the disadvantages of conventional lecithin matrices can be overcome.
- Lecithin matrices the water content is always low due to the strongly lipophilic properties of the matrix and the water present does not move freely in the matrix, but is bound to the polar head groups and hydrates them or hydrolyzes the head group. This causes the instability of the phospholipid (i.e. PC or PS) in conventional matrices.
- a polyalcohol component according to the invention for example glycerol as the polar substance, displaces the water from the head group and thereby prevents or at least delays the hydrolysis of the phospholipid.
- the matrix therefore preferably contains at least one fat component in addition to PS and PC, even more preferably a fat component and wax component, and in a further embodiment preferably at least one polyalcohol component.
- particularly suitable as matrix materials are substances which enable complete encapsulation to be achieved, and substances which provide a matrix with high stability and low shear stress.
- the claimed matrix has a water-containing covering, which can also be permanently elastic.
- the coating which preferably also consists of gelatin, glycerol, sugar (alcohols), starch, polysaccharides and mixtures thereof, should have a water content of 1.0 to 10.0% by weight, based on the total coating. Sorbitol is particularly preferred as sugar alcohols for the coating and carrageenans, alginates and / or pectins as polysaccharide components.
- the coating of the matrix contains, as further additives, silicon dioxide, calcium carbonate, food-grade dyes, color pigments and / or talc.
- weight ratios of the coating to the bioactive component which are between 1: 0.25 to 10.0 and particularly preferably 1: 1 to 5.0, have been found to be particularly suitable.
- the total diameter of the matrix is, of course, also dependent on the respective intended use, and should in particular be between 0.3 and 20 mm according to the present invention.
- the present invention also claims its use, with the components contained in it in particular strengthening the mental and / or physical endurance and performance, preventing elevated serum cholesterol levels, promoting or / and maintaining health, and in general the focus is on improving well-being.
- the matrix according to the invention With the matrix according to the invention, a formulation of phosphatidylserine and phosphatidylcholine was thus found which can be prepared in an economically justifiable manner and which, in contrast to the known other formulations, has a pronounced oxidative and hydrolytic stability.
- the matrix according to the invention thus combines two features that were previously incompatible, namely being encapsulable and at the same time having sufficient stability. This combination is particularly pronounced for matrices with thixotropic or shear-thinning properties. But it also occurs in matrix forms that are pasty and behave in a Newtonian way.
- the following examples illustrate these advantages of the matrix with a bioactive, phospholipid-containing component according to the invention.
- the hard matrix contained 20% by weight of phosphatidylserine and 15% by weight of phosphatidylcholine as the bioactive component. Further constituents were in each case 3% by weight of phosphatidylinositol and 2% by weight of phosphatidylethanolamine, 38% by weight of a mixture of refined soybean oils, two partially hydrogenated soybean oils of different melting points and 3% by weight of a beeswax, 2% by weight % of a mixture consisting of vitamins E and D, tocotrieole and R-carotene. The remaining 100% by weight consisted of the typical lecithin accompanying substances such as glycolipids, phytosterols and oligosugars.
- the two bioactive components were homogeneously distributed in the matrix, which was in the form of pellets with a diameter of 3 to 8 mm.
- the hard matrix contained 20% by weight of phosphatidylserine, 5% by weight of phosphatidylcholine and 4% by weight of phosphatidylinositol as the bioactive component. Further constituents were in each case 6% by weight of phosphatidylethanolamine and 2% by weight of phosphatidic acid, 45% by weight of palm kernel oil and 5% by weight of a beeswax and 0.2% of vitamin E. The rest of 100% by weight consisted of the typical lecithin accompanying substances such as glycolipids, phytosterols and oligosugars.
- Example 3 Example 3:
- the hard matrix contained 30% by weight of phosphatidylserine, 4% by weight of phosphatidylcholine and 2% by weight of phosphatidylinositol as the bioactive component. Further constituents were in each case 4% by weight of phosphatidylethanolamine and 1% by weight of phosphatidic acid, 45% by weight of palm kernel oil and 5% by weight of a beeswax and 0.2% of vitamin E. The rest consisted of 100% by weight from the typical lecithin accompanying substances such as glycolipids, phytosterols and oligosugars.
- Table 1 shows that, for example, the very hydrolysis-sensitive phosphatidylserine (PS) encapsulated in a soft gelatin capsule, that embedding the phospholipids in the matrix according to the invention effects, among other things, a stabilizing effect against hydrolysis.
- PS very hydrolysis-sensitive phosphatidylserine
- Examples 1 to 3 are the three described examples of the invention; Examples 4 to 6 are comparative examples. Table 1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003229693A AU2003229693A1 (en) | 2002-04-19 | 2003-04-17 | Matrix comprising a bioactive component containing phospholipid |
EP03722502A EP1503742A2 (de) | 2002-04-19 | 2003-04-17 | Matrix mit einer bioaktiven phospholipid-haltigen komponente |
JP2003585701A JP4599604B2 (ja) | 2002-04-19 | 2003-04-17 | 生体活性のリン脂質含有成分を含有するマトリックス |
US10/511,888 US20050232996A1 (en) | 2002-04-19 | 2003-04-17 | Matrix comprising a bioactive component containing phospholipid |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10217558 | 2002-04-19 | ||
DE10217558.6 | 2002-04-19 | ||
DE10250727A DE10250727B4 (de) | 2002-04-19 | 2002-10-31 | Matrix mit einer bioaktiven Phospholipid-haltigen Komponente |
DE10250727.9 | 2002-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003088949A2 true WO2003088949A2 (de) | 2003-10-30 |
WO2003088949A3 WO2003088949A3 (de) | 2004-12-16 |
Family
ID=29251774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/004030 WO2003088949A2 (de) | 2002-04-19 | 2003-04-17 | Matrix mit einer bioaktiven phospholipid-haltigen komponente |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050232996A1 (de) |
EP (1) | EP1503742A2 (de) |
JP (1) | JP4599604B2 (de) |
AU (1) | AU2003229693A1 (de) |
WO (1) | WO2003088949A2 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008546845A (ja) * | 2005-06-28 | 2008-12-25 | ケージーケー シナガイズ インク. | 心臓血管疾患の治療のためのポリメトキシフラボン類およびトコトリエノール類のバイオアベイラビリティーを改善する組成物 |
DE102007042557A1 (de) | 2007-09-07 | 2009-03-19 | Membramed Gmbh | Neuartige Formulierung von Phospholipiden |
US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US8324187B2 (en) | 2003-09-25 | 2012-12-04 | Enzymotec Ltd. | Stabilized formulations of phosphatidylserine |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2847207B1 (de) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Nanokristalle von Fluticasonpropionat |
EP3596182B1 (de) | 2017-03-17 | 2021-06-30 | Dow Global Technologies LLC | Epoxid-acryl-hybridklebstoff |
JP7182630B2 (ja) * | 2017-11-27 | 2022-12-02 | カーギル インコーポレイテッド | 二重エマルジョン |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011294A1 (en) * | 1990-12-20 | 1992-07-09 | Fidia S.P.A. | Heparin derivatives |
WO1993021190A1 (en) * | 1992-04-17 | 1993-10-28 | Fidia S.P.A. | Method for the preparation and purification of phospholipid mixtures free from contamination by unconventional viruses |
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1212900B (it) * | 1983-11-17 | 1989-11-30 | Valle Francesco Della | Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna |
US5091187A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5342626A (en) * | 1993-04-27 | 1994-08-30 | Merck & Co., Inc. | Composition and process for gelatin-free soft capsules |
US6103271A (en) * | 1994-12-02 | 2000-08-15 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulation and electrostatic processing method |
FR2729296B1 (fr) * | 1995-01-12 | 1997-03-28 | Europlanaire | Compositions pharmaceutiques comprenant une superoxyde dismutase |
JPH10330250A (ja) * | 1997-06-03 | 1998-12-15 | Toyo Capsule Kk | メナテトレノン油性製剤 |
US6004571A (en) * | 1997-09-04 | 1999-12-21 | Thies; Curt | Simulated insect eggs |
KR100607008B1 (ko) * | 1997-12-26 | 2006-08-01 | 워너-램버트 캄파니 엘엘씨 | 젤라틴 조성물 |
EP1059941B1 (de) * | 1998-03-05 | 2004-05-26 | Phares Pharmaceutical Research N.V. | Arzneimittel und deren verwendung |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
JP2001247453A (ja) * | 2000-03-09 | 2001-09-11 | Marin Pharm:Kk | ソフトカプセル用皮膜及びソフトカプセル剤 |
EP1267890A2 (de) * | 2000-04-07 | 2003-01-02 | The Board of Regents of The University of Texas System | Einzige zusammensetzungen aus zwitterionischen phospholipiden und bisphosphonaten mit reduzierter toxizität und erhöhter bioverfügbarkeit |
-
2003
- 2003-04-17 WO PCT/EP2003/004030 patent/WO2003088949A2/de active Application Filing
- 2003-04-17 JP JP2003585701A patent/JP4599604B2/ja not_active Expired - Fee Related
- 2003-04-17 AU AU2003229693A patent/AU2003229693A1/en not_active Abandoned
- 2003-04-17 EP EP03722502A patent/EP1503742A2/de not_active Withdrawn
- 2003-04-17 US US10/511,888 patent/US20050232996A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992011294A1 (en) * | 1990-12-20 | 1992-07-09 | Fidia S.P.A. | Heparin derivatives |
WO1993021190A1 (en) * | 1992-04-17 | 1993-10-28 | Fidia S.P.A. | Method for the preparation and purification of phospholipid mixtures free from contamination by unconventional viruses |
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8324187B2 (en) | 2003-09-25 | 2012-12-04 | Enzymotec Ltd. | Stabilized formulations of phosphatidylserine |
US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
JP2008546845A (ja) * | 2005-06-28 | 2008-12-25 | ケージーケー シナガイズ インク. | 心臓血管疾患の治療のためのポリメトキシフラボン類およびトコトリエノール類のバイオアベイラビリティーを改善する組成物 |
DE102007042557A1 (de) | 2007-09-07 | 2009-03-19 | Membramed Gmbh | Neuartige Formulierung von Phospholipiden |
Also Published As
Publication number | Publication date |
---|---|
JP2006504628A (ja) | 2006-02-09 |
EP1503742A2 (de) | 2005-02-09 |
US20050232996A1 (en) | 2005-10-20 |
JP4599604B2 (ja) | 2010-12-15 |
AU2003229693A1 (en) | 2003-11-03 |
AU2003229693A8 (en) | 2003-11-03 |
WO2003088949A3 (de) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69818704T2 (de) | Verfahren zur verbesserung der absorption und des transport von lipidlöslichen verbindungen mittels strukturierter glyceriden | |
EP0551638B1 (de) | Stabile, flüssige Präparate fettlöslicher Substanzen | |
EP0859626B1 (de) | Cyclosprorin(e) enthaltende pharmazeutische zubereitung zur oralen applikation und verfahren zu ihrer herstellung | |
WO2003088761A2 (de) | Physiologisch verträgliche, phospholipid-haltige, stabile und harte matrix | |
EP1028722A1 (de) | Pharmazeutisch wirksame zusammensetzung enthaltend artemisinin und/oder ein derivat von artemisinin | |
DE212015000033U1 (de) | Therapeutische Astaxanthin- und Phospholipidzusammensetzung | |
DE3613799C1 (de) | Verwendung von Glycofurol zum Verfluessigen von Arzneimittelzubereitungen fuer das Abfuellen in Weichgelatinekapseln | |
WO2003088949A2 (de) | Matrix mit einer bioaktiven phospholipid-haltigen komponente | |
WO2016169941A1 (de) | Gelkapsel enthaltend sterol und solubilisator | |
EP1660097B1 (de) | Physiologisch aktive zusammensetzung auf phosphatidylserin-basis | |
DE10250727B4 (de) | Matrix mit einer bioaktiven Phospholipid-haltigen Komponente | |
JP6445239B2 (ja) | ソフトカプセル充填組成物及び該ソフトカプセル充填組成物が充填されたソフトカプセル | |
EP3801070B1 (de) | Zweiphasiges system | |
WO2020143910A1 (de) | Zweiphasiges system | |
DE10221212A1 (de) | Sporopollenin enthaltende lösliche Zusammensetzung und Verwendung | |
CN108368451A (zh) | 油脂组合物和油脂的氧化抑制方法 | |
TWI759659B (zh) | 脂質體、水性組成物以及脂質體製造方法 | |
JP2018145148A (ja) | ソフトカプセル剤 | |
DE202020104968U1 (de) | Sprühfähige Zusammensetzung eines Rachensprays | |
DE19520659A1 (de) | Pharmazeutische Zubereitung zur Therapie und/oder Prophylaxe von durch Viren bedingten Erkrankungen der Haut und/oder der Schleimhaut | |
JP2018095634A (ja) | カプセル用組成物及びカプセル剤 | |
KR102524312B1 (ko) | 엑디스테로이드 함유 수용성 유화 조성물 | |
EP0841057A2 (de) | Phospholipidische Zusammensetzung, Verfahren zur Herstellung einer derartigen Zusammensetzung und Verwendung derselben | |
EP3057578A1 (de) | Zusammensetzung zur oralen administration von curcumin | |
DE19505305A1 (de) | Stabilisierte Lipidzusammensetzung mit langkettig-hochungesättigten Fettsäuren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10511888 Country of ref document: US Ref document number: 2003585701 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003722502 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003722502 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |